According to HDFC Securities, approvals for significant products like gSynthroid will trigger a re-rating for Lupin. The brokerage expects Lupins US revenues to grow at least in mid-single digit in FY19, along with strong double digit growth in emerging market segments including India.
Market Dashboard
